Pharmacogenetics of Antiplatelet Therapy

Genetics (AJ Marian, Section Editor)

DOI: 10.1007/s11883-014-0411-7

Cite this article as:
Daly, P.L. & Becker, R.C. Curr Atheroscler Rep (2014) 16: 411. doi:10.1007/s11883-014-0411-7
Part of the following topical collections:
  1. Topical Collection on Genetics


There has been substantial progress toward understanding and investigating the specific genetic factors that influence interindividual variations in platelet-directed therapy. There has also been substantial progress toward better understanding of the pharmacogenetics of drug metabolism and phamacodynamic response to platelet antagonists. We summarize the relationship between genetic polymorphisms, response to platelet antagonists, and clinical impact on patient treatment for the commonly used antiplatelet drugs. The challenge faced in translating genotype identification into improved clinical outcomes reflects the complexity involved in the genomic influence on drug metabolism and activation.


Pharmacogenetics Antiplatelet therapy Clopidogrel Prasugrel Ticagrelor Genetic 

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Division of Cardiovascular Health and DiseaseUniversity of Cincinnati Medical Center, University of Cincinnati College of MedicineCincinnatiUSA

Personalised recommendations